These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 2741811

  • 1. Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
    Kuchar DL, Garan H, Venditti FJ, Finkelstein D, Rottman JN, McComb J, McGovern BA, Ruskin JN.
    Am J Cardiol; 1989 Jul 01; 64(1):33-6. PubMed ID: 2741811
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease.
    Young GD, Kerr CR, Mohama R, Boone J, Yeung-Lai-Wah JA.
    Am J Cardiol; 1994 Apr 01; 73(9):677-82. PubMed ID: 8166065
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
    Haverkamp W, Martinez-Rubio A, Hief C, Lammers A, Mühlenkamp S, Wichter T, Breithardt G, Borggrefe M.
    J Am Coll Cardiol; 1997 Aug 01; 30(2):487-95. PubMed ID: 9247523
    [Abstract] [Full Text] [Related]

  • 4. [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
    Trappe HJ, Klein H, Lichtlen PR.
    Z Kardiol; 1987 Oct 01; 76(10):630-4. PubMed ID: 3687165
    [Abstract] [Full Text] [Related]

  • 5. Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias.
    Hoppe UC, Haverkamp W, Breithardt G, Borggrefe M.
    Pacing Clin Electrophysiol; 2000 May 01; 23(5):854-62. PubMed ID: 10833706
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias.
    Gonzalez R, Scheinman MM, Herre JM, Griffin JC, Sauve MJ, Sharkey H.
    J Am Coll Cardiol; 1988 Dec 01; 12(6):1568-72. PubMed ID: 3192854
    [Abstract] [Full Text] [Related]

  • 8. Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
    Mewis C, Kühlkamp V, Mermi J, Bosch RF, Seipel L.
    J Am Coll Cardiol; 1999 Jun 01; 33(7):1989-95. PubMed ID: 10362204
    [Abstract] [Full Text] [Related]

  • 9. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
    Steinbeck G, Bach P, Haberl R.
    J Am Coll Cardiol; 1986 Oct 01; 8(4):949-58. PubMed ID: 3760368
    [Abstract] [Full Text] [Related]

  • 10. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
    Nademanee K, Singh BN.
    Am J Cardiol; 1990 Jan 02; 65(2):53A-57A; discussion 65A-66A. PubMed ID: 2403735
    [Abstract] [Full Text] [Related]

  • 11. Sotalol in patients with life-threatening ventricular tachyarrhythmias.
    Trappe HJ, Klein H, Lichtlen P.
    Cardiovasc Drugs Ther; 1990 Oct 02; 4(5):1425-32. PubMed ID: 2278875
    [Abstract] [Full Text] [Related]

  • 12. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG, Martins JB, Wendt DJ, Constantin L, Hopson R, McCue ML.
    Am J Cardiol; 1988 May 01; 61(13):1012-7. PubMed ID: 3129926
    [Abstract] [Full Text] [Related]

  • 13. Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
    Jordaens LJ, Palmer A, Clement DL.
    Eur Heart J; 1989 Mar 01; 10(3):218-26. PubMed ID: 2707270
    [Abstract] [Full Text] [Related]

  • 14. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
    Kühlkamp V, Mewis C, Mermi J, Bosch RF, Seipel L.
    J Am Coll Cardiol; 1999 Jan 01; 33(1):46-52. PubMed ID: 9935007
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Response to sotalol predicts the response to amiodarone during serial drug testing in patients with sustained ventricular tachycardia and coronary artery disease.
    Martínez-Rubio A, Shenasa M, Chen X, Wichter T, Breithardt G, Borggrefe M.
    Am J Cardiol; 1994 Feb 15; 73(5):357-60. PubMed ID: 7509121
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
    Kus T, Campa MA, Nadeau R, Dubuc M, Kaltenbrunner W, Shenasa M.
    Am Heart J; 1992 Jan 15; 123(1):82-9. PubMed ID: 1729853
    [Abstract] [Full Text] [Related]

  • 19. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease.
    Böcker D, Haverkamp W, Block M, Borggrefe M, Hammel D, Breithardt G.
    Circulation; 1996 Jul 15; 94(2):151-7. PubMed ID: 8674173
    [Abstract] [Full Text] [Related]

  • 20. Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction.
    Koch KT, Düren DR, van Zwieten PA.
    Cardiovasc Drugs Ther; 1995 Jun 15; 9(3):437-43. PubMed ID: 8527354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.